Fawaz Arshad
Sheffield, UK
Mon 24 16:20
OC18
Oral Communications
Developing a human-mouse hybrid model of osteogenesis imperfecta for investigating new therapies for children
Sheffield, UK
Tandy Aye
California, USA
Mon 24
P17
Allied Health Professionals Session
Sex and maturation effects on trabecular and cortical microarchitecture in children and young adults
California, USA
Mon 24
P17
Moderated ePosters
Sex and maturation effects on trabecular and cortical microarchitecture in children and young adults
California, USA
Meena Balasubramanian
Sheffield, UK
Mon 24 16:40
OC20
Oral Communications
Identifying the role of NBAS in bone fragility using zebrafish and exploring therapeutic targets to reverse NBAS activity
Sheffield, UK
Jas Basraka
Birmingham, UK
Sat 22 10:05
Networking - Allied Health Professionals
Management of children with severe osteogenesis imperfecta / Patient experiences seen through ‘Stop Motion’ animation
Birmingham, UK
Genevieve Baujat
Paris, France
Sun 23
P99
Moderated ePosters
Pre and post-natal achondroplasia, retrospective series of 64 consecutives cases with analyze of the diagnostic methods and timing issues
Paris, France
Nick Bishop
Sheffield, UK
Sat 22 14:30
Bone fragility during childhood - beyond osteogenesis imperfecta
Infant case
Sheffield, UK
Sun 23
P133
Moderated ePosters
Losartan reduces circulating TGFb and CTX and increases vertebral bone mass in the OIM mouse
Sheffield, UK
James Blackburn
Liverpool, UK
Sun 23
P129
Moderated ePosters
A smartphone based survey of frequency and severity of adverse effects following bisphosphonate therapy in a tertiary paediatric centre
Liverpool, UK
Stéphane Blouin
Vienna, Austria
Sun 23 11:50
OC3
Oral Communications
Osteocyte lacunae characteristics in healthy children
Vienna, Austria
Melanie Boeyer
Missouri, United States
Mon 24
P13
Moderated ePosters
Clinical implications of modeling the maturational spurt
Missouri, United States
Iris Boraschi-Diaz
Montreal, Canada
Mon 24 11:20
OC12
Oral Communications
Combination treatment of a novel activin receptor IIB ligand trap and zoledronate improves muscle and bone proprieties in a mouse model of osteogenesis imperfecta
Montreal, Canada
Stephanie Borg
Sheffield, UK
Sun 23 15:30
OC4
Oral Communications
Early life vitamin D depletion and mechanical loading determine methylation changes in the RXRA, Runx2 and osterix promoters in mice
Sheffield, UK
Alison Boyce
Bethesda, USA
Sat 22 13:30
Challenge the Expert
Case 1: Fibrous dysplasia
Bethesda, USA
Tue 25 08:00
Meet the Expert
Management of fibrous dysplasia
Bethesda, USA
Avivit Brener
Tel Aviv, Israel
Sun 23
P127
Moderated ePosters
Burosumab therapy in pediatric patients with X-linked hypophosphatemia improves body composition
Tel Aviv, Israel
Alistair Calder
London, UK
Sat 22 10:35
Networking - Allied Health Professionals
Imaging in metabolic bone disease
London, UK
Lan Cheng
Bremen, Germany
Mon 24
P107
Moderated ePosters
Sex differences in the longitudinal associations between body composition and bone stiffness index in European children and adolescents
Bremen, Germany
Amish Chinoy
Manchester, United Kingdom
Sun 23
P70
Moderated ePosters
Metabolic bone disease of prematurity – comparing neonatal and endocrine approaches using a nationwide survey
Manchester, United Kingdom
Patricia Clark
Mexico City, Mexico
Mon 24
P109
Moderated ePosters
Fracture prevalence in children 0-19 years-old in Mexico: A 10-year cross-sectional analysis
Mexico City, Mexico
Alessandra Cocca
London, UK
Sun 23
P221
Moderated ePosters
Speech and hearing impairment and respiratory complications in a large cohort of patients with achondroplasia
London, UK
Samuel Collins
Basel, Switzerland
Tue 25 10:10
OC24
Oral Communications
TA-46, a recombinant soluble FGFR3 receptor for the treatment of achondroplasia, is safe and well-tolerated in healthy volunteers
Basel, Switzerland
Valérie Cormier-Daire
Paris, France
Tue 25 09:00
IS15
An update on skeletal dysplasias
Diagnosis of bone dysplasia
Paris, France
Nicola Crabtree
Birmingham, UK
Tue 25 10:55
LB2
Oral Communications
Lumbar spine quantitative computed tomography (QCT) is a better predictor of vertebral fracture in boys with Duchenne muscular dystrophy (DMD) than either DXA or peripheral QCT
Birmingham, UK
Elizabeth Curtis
Southampton, UK
Sun 23 15:40
OC5
Oral Communications
Low birthweight is associated with poorer limb muscle mass and grip strength in middle age: findings from the UK Biobank Imaging Enhancement
Southampton, UK
Katherine Cygnar
Tarrytown, United States
Mon 24 11:00
OC10
Oral Communications
Next-generation antibody-guided enzyme replacement therapy for lysosomal storage diseases
Tarrytown, United States
Natascia Di Iorgi
Mon 24
P18
Moderated ePosters
Bone mass and fracture prevalence in Childhood Brain Cancer Survivors (CBCS) 2 or 5 years after off therapy
Artemis Doulgeraki
Athens, Greece
Mon 24
P23
Moderated ePosters
What happens to the skeleton at the time of diagnosis of paediatric cancer?
Athens, Greece
Jos Draaisma
Nijmegen, Netherlands
Mon 24
P83
Moderated ePosters
Could digital X-ray radiogrammetry be an alternative for dual energy X-ray absorptiometry
Nijmegen, Netherlands
Rachel Duckham
Geelong, Australia
Mon 24
P9
Allied Health Professionals Session
Do lifestyle factors play a role on bone health in boys diagnosed with Autism Spectrum Disorder? Preliminary data from the Promoting bone and gut health in our children (PROUD) study
Geelong, Australia
Mon 24
P9
Moderated ePosters
Do lifestyle factors play a role on bone health in boys diagnosed with Autism Spectrum Disorder? Preliminary data from the Promoting bone and gut health in our children (PROUD) study
Geelong, Australia
Ahmed Elhakeem
Bristol, UK
Sun 23 11:30
OC1
Oral Communications
Association between age at puberty and bone accrual up to 25 years-old
Bristol, UK
Marta Erlandson
Saskatoon, Canada
Mon 24
P14
Moderated ePosters
Bone health in children with congenital heart disease
Saskatoon, Canada
François Fassier
Montreal, Canada
Mon 24 14:00
IS12
Surgical aspects in rare bone disorders
Orthopedic management of osteogenesis imperfecta in the bisphosphonate era
Montreal, Canada
David Fennimore
Sheffield, UK
Mon 24
P93
Allied Health Professionals Session
Assessing the ability of vibration analysis to differentiate wrist and ankle fractures from sprains in children
Sheffield, UK
Mon 24
P93
Moderated ePosters
Assessing the ability of vibration analysis to differentiate wrist and ankle fractures from sprains in children
Sheffield, UK
Sacha Flammier
Lyon, France
Mon 24
P143
Moderated ePosters
Intermittent bi-daily sub-cutaneous teriparatide infusion in children with hypoparathyroidism: a single-centre experience
Lyon, France
Antonella Forlino
Pavia, Italy
Mon 24 09:30
IS10
Bone cells
Endoplasmic reticulum stress in osteoblasts
Pavia, Italy
Rudolf Ganger
Vienna, Austria
Mon 24 15:00
IS14
Surgical aspects in rare bone disorders
Orthopedic needs in X-linked hypophosphatemic rickets
Vienna, Austria
Robyn Gilbey-Cross
London, UK
Mon 24
P74
Allied Health Professionals Session
Burosumab can improve pain and quality of life for children with X-linked hypophosphataemia and their families: a London centre’s experience
London, UK
Vicente Gilsanz
Los Angeles, USA
Sun 23 10:00
IS5
Bone development
Spine development
Los Angeles, USA
Sujatha Gopal
Sheffield, UK
Sun 23
P5
Moderated ePosters
Response of bone to mechanical stimulation in the offspring of MAVIDOS study mothers in a single centre; the effect of antenatal vitamin D supplementation
Sheffield, UK
Ingo Grafe
Houston, USA
Tue 25 11:30
IS17
Approaches to treating low bone mass disorders
TGFbeta inhibition in osteogenesis imperfecta
Houston, USA
Rachel Harrison
Sheffield, UK
Mon 24
P25
Moderated ePosters
Short term mechanical stimulation using whole body vibration identifies differences in bone response between prepubertal boys with and without prior fracture
Sheffield, UK
Sarah Hatsell
Tarrytown, United States
Sun 23
P121
Moderated ePosters
An Acvr1[R258G] “conditional on” mouse model of atypical fibrodysplasia ossificans progressiva (FOP) is activin A dependent
Tarrytown, United States
Catherine Hawrylowicz
London, UK
Sun 23 15:00
IS8
Vitamin D
Vitamin D in pregnancy and offspring immunology
London, UK
Ghazal Hedjazi
Vienna, Austria
Mon 24 17:00
OC22
Oral Communications
Bone tissue phenotyping reveals increased matrix mineralization, elevated osteocyte lacunar density and altered vascularity in a new OI mouse model carrying a leucine substitution for the BRIL p.Serine42 residue
Vienna, Austria
Wolfgang Högler
Linz, Austria
Sun 23 14:00
IS6
Vitamin D
Nutritional rickets – a socioeconomic problem
Linz, Austria
Sun 23 15:50
OC6
Oral Communications
Anthropometric characteristics of pediatric patients with hypophosphatasia: data from the Global Hypophosphatasia Patient Registry
Linz, Austria
Mon 24 11:50
OC15
Oral Communications
Sustained efficacy and safety of burosumab, a fully human anti-FGF23 monoclonal antibody, in children and early adolescents with X-linked hypophosphatemia
Linz, Austria
Rachel Hoyer-Kuhn
Melbourne, Germany
Sat 22
Networking - New Investigators
How did I get here?
Melbourne, Germany
Zilla Huma
Sun 23
P42
Moderated ePosters
FGF 23 measurements in children with fibrous dysplasia: useful or not?
Alex Ireland
Manchester, UK
Sun 23 08:00
Meet the Expert
Assessment of neuromuscular function and physical activity
Manchester, UK
Mon 24
P163
Moderated ePosters
Prenatal oligohydramnios is associated with hip shape in adolescent males
Manchester, UK
Stefan Jackowski
Ottawa, Canada
Sun 23
P46
Moderated ePosters
Vertebral fractures are more prevalent than long bone fractures in boys with glucocorticoid-treated Duchenne Muscular Dystrophy: Results of a prospective observational study
Ottawa, Canada
Mon 24
P164
Moderated ePosters
Musculoskeletal deficits persist up to two years despite anti-TNF-alpha antibody therapy in children with Crohn’s disease: Results of a prospective, observational inception cohort study
Ottawa, Canada
Rebecca Jones
Sheffield, UK
Mon 24
P197
Allied Health Professionals Session
A playful type of intervention for infants with osteogenesis imperfecta
Sheffield, UK
Masanobu Kawai
Osaka, Japan
Mon 24 10:00
IS11
Bone cells
Clock genes and bone and mineral regulation
Osaka, Japan
Richard Keen
Stanmore, UK
Tue 25 10:40
OC27
Oral Communications
Palovarotene inhibits the development of new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP)
Stanmore, UK
Anuradha Khadilkar
Pune, India
Sun 23 11:40
OC2
Oral Communications
Adolescent pregnancy and bone density in premenopausal women
Pune, India
Takeshi Kimura
Osaka, Japan
Tue 25 10:00
OC23
Oral Communications
Effects of the FGF2 aptamer on growth plate cartilage development of achondroplasia patient-specific iPS cells in a xenograft model
Osaka, Japan
Joseph Kindler
Philadelphia, United States
Sun 23
P63
Moderated ePosters
Bone geometry and microarchitecture deficits in children with Alagille Syndrome
Philadelphia, United States
Mon 24
P94
Moderated ePosters
Characteristics of ultradistal radius bone density during childhood: Results from the Bone Mineral Density in Childhood Study
Philadelphia, United States
Klaus Klaushofer
Vienna, Austria
Sun 23 08:00
Meet the Expert
What you need to know about bone histomorphometry
Vienna, Austria
Mikhail Kostik
St Petersburg, Russian Federation
Mon 24
P113
Moderated ePosters
Next-generation sequence and biomarker levels in the patients with early-onset chronic non-bacterial osteomyelitis from North Caucasian region of Russia
St Petersburg, Russian Federation
Kristina Kulikova
Moscow, Russian Federation
Mon 24
P120
Moderated ePosters
Mutational and phenotypic spectra in 137 Russian patients with inherited forms of rickets
Moscow, Russian Federation
Craig Langman
Chicago, USA
Mon 24 08:00
Meet the Expert
Skeletal involvement in chronic kidney diseases
Chicago, USA
Lucinda Lee
Westmead, Australia
Mon 24 11:10
OC11
Oral Communications
Targeting adeno-associated viral vectors to fractures and the skeleton
Westmead, Australia
Laura Leoni
Pavia, Italy
Sun 23
P37
Moderated ePosters
Generation of osteogenesis imperfecta type XIV zebrafish models
Pavia, Italy
Agnès Linglart
Paris, France
Sun 23 08:00
Meet the Expert
Therapeutic management of hypophosphatemic rickets
Paris, France
Outi Mäkitie
Helsinki, Finland
Tue 25 08:00
Meet the Expert
Genetic testing for recurrent fractures – when and what?
Helsinki, Finland
Meng Mao
Novato, United States
Mon 24 16:10
OC17
Oral Communications
Growth curves for children with X-linked hypophosphatemia
Novato, United States
Jill Massey
London, UK
Sat 22 10:50
Networking - Allied Health Professionals
From conception to the retailer. How to make your specialised equipment commercially available
London, UK
Richard McGee
Westmead, Australia
Mon 24
P199
Moderated ePosters
Diversity of outcomes in randomised trials of interventions for children with osteogenesis imperfecta
Westmead, Australia
Toshimi Michigami
Izumi, Japan
Sun 23
P114
Moderated ePosters
Hypophosphatasia in Japan: ALPL mutation analysis in 98 patients
Izumi, Japan
Gabriel Mindler
Vienna, Austria
Sat 22 11:05
Networking - Allied Health Professionals
Surgery and rehabilitation for children with
Vienna, Austria
Rebecca Moon
Southampton, UK
Mon 24
P154
Moderated ePosters
Self-reported sedentary time is negatively associated with microarchitecture of the tibia
Southampton, UK
Mon 24
P22
Moderated ePosters
Tibia microarchitecture in children with recent fractures
Southampton, UK
Zulf Mughal
Dubai , UAE
Sun 23
P75
Moderated ePosters
Active vitamin D analogues and oral phosphate for the treatment of X-linked hypophosphataemia in paediatric patients: A systematic literature review and survey of expert opinion on current needs
Dubai , UAE
Mon 24 08:00
Meet the Expert
Bone in neuromuscular disorders
Dubai , UAE
Craig Munns
Brisbane, Australia
Sat 22 14:10
Challenge the Expert
Case 3: Bone fragility, abnormal neurology and bleeding disorder – a challenging case
Brisbane, Australia
Sat 22 15:10
Bone fragility during childhood - beyond osteogenesis imperfecta
Adolescent case
Brisbane, Australia
Sun 23 16:10
OC8
Oral Communications
Bisphosphonate improves hip range of motion and pain but not femoral head sphericity. A multicentre, randomized clinical trial of children with Perthes disease
Brisbane, Australia
Noriyuki Namba
Osaka, Japan
Tue 25 09:30
IS16
An update on skeletal dysplasias
Current care and new therapeutic approaches to achondroplasia
Osaka, Japan
Kalyan Nannuru
Tarrytown, United States
Sun 23
P212
Moderated ePosters
Genetic loss of heparanase does not inhibit osteochondromas in Ext1 and Ext2 double heterozygous hereditary multiple osteochondroma mouse model
Tarrytown, United States
Coen Netelenbos
Amsterdam, Netherlands
Tue 25 10:30
OC26
Oral Communications
[18F] NaF PET/CT the first tool to diagnose chronic activity in FOP at all ages?
Amsterdam, Netherlands
Yvonne Nitschke
Münster, Germany
Mon 24 16:00
OC16
Oral Communications
A natural history study of generalized arterial calcification of infancy (GACI) and autosomal recessive hypophosphatemic rickets (ARHR2) due to ENPP1 or ABCC6 deficiency: Interim analysis
Münster, Germany
Munier Nour
Sun 23
P81
Moderated ePosters
Bone health in adolescent females with anorexia nervosa may be preserved by high lean mass
Niamh Nowlan
London, UK
Sun 23 09:00
IS3
Bone development
Biomechanics of fetal movements
London, UK
Gillian O'Donnell
Dublin, Ireland
Mon 24
P125
Moderated ePosters
SCN8a mutations and osteoporosis. Is osteocyte dysfunction the cause or the consequence?
Dublin, Ireland
Verity Pacey
Westmead, Australia
Mon 24
P181
Allied Health Professionals Session
Walking quality of children with healed Perthes disease
Westmead, Australia
Mon 24
P181
Moderated ePosters
Walking quality of children with healed Perthes disease
Westmead, Australia
Raja Padidela
Manchester, UK
Sun 23
P110
Moderated ePosters
Cost-effectiveness of a vitamin D supplementation programme in pregnant women and children to prevent rickets in the UK
Manchester, UK
Sonal Palande
Pune, India
Sun 23
P174
Moderated ePosters
Supplementation of children with type 1 diabetes with milk or pharmacological calcium for improving bone health: A randomized controlled trial
Pune, India
Mon 24
P41
Moderated ePosters
Increased prevalence of fractures in poorly chelated children with beta thalassemia
Pune, India
Mon 24
P87
Moderated ePosters
Assessment of bone density by DXA in poorly controlled children with β-Thalassemia: Correction for hepatic iron -overloadby manual analysis
Pune, India
Mon 24
P89
Moderated ePosters
Use of DXA and pQCT measurements to screen for fracture risk in 3 to 18 year old poorly chelated thalassaemic children
Pune, India
Mon 24
P155
Moderated ePosters
Gender specific paediatric reference data for muscle function parameters assessed using jumping mechanography
Pune, India
Mon 24
P159
Moderated ePosters
Determinants of muscle function in 6 to 11 year old rural Indian children
Pune, India
Kristen Pan
Bethesda, USA
Sun 23
P220
Moderated ePosters
New perspectives in diagnosis and management of optic neuropathy in fibrous dysplasia: utility of optical coherence tomography and computed tomography measurements
Bethesda, USA
Amanda Peacock
Sheffield, UK
Mon 24
P137
Moderated ePosters
Reversion to pamidronate after switch to zoledronic acid in children with bone disease
Sheffield, UK
Susanne Pozza
Munich, Germany
Sun 23
P156
Moderated ePosters
Patients with nephropatic cystinosis display lower cortical thickness and grip strength
Munich, Germany
Adalbert Raimann
Vienna, Austria
Mon 24
P79
Allied Health Professionals Session
Novel imaging approaches to the quantification of musculoskeletal alterations in X-linked hypophosphatemic rickets (XLH)
Vienna, Austria
Gali Ram
Bethesda, USA
Mon 24 16:50
OC21
Oral Communications
New mouse model with IFITM5 S42L for atypical type VI osteogenesis imperfecta
Bethesda, USA
Guylene Rignol
Nice, France
Sun 23
P15
Moderated ePosters
TA-46 prevents premature synchondrosis and restores foramen magnum size in a mouse model of achrondroplasia
Nice, France
Marie-Eve Robinson
Montreal, Canada
Sun 23
P150
Moderated ePosters
Osteogenesis imperfecta: Skeletal outcomes after bisphosphonates discontinuation at final height
Montreal, Canada
Sun 23
P151
Moderated ePosters
The safety and efficacy of denosumab versus zoledronic acid in the treatment of pediatric osteoporosis: A randomized controlled pilot trial
Montreal, Canada
Sun 23
P152
Moderated ePosters
An evaluation of the rebound phenomenon during denosumab therapy in children with low turnover osteoporosis
Montreal, Canada
Federico Rocco
Lyon, France
Mon 24 14:30
IS13
Surgical aspects in rare bone disorders
Craniosynostoses in rare skeletal disorders
Lyon, France
Frank Rutsch
Münster, Germany
Mon 24 08:00
Meet the Expert
Ectopic mineralization
Münster, Germany
Jean-Pierre Salles
Toulouse, France
Sat 22 14:50
Bone fragility during childhood - beyond osteogenesis imperfecta
Child case
Toulouse, France
Oliver Semler
Cologne, Germany
Tue 25 08:00
Meet the Expert
Vibration treatment
Cologne, Germany
Sumudu Seneviratne
Colombo, Sri Lanka
Mon 24
P16
Moderated ePosters
Higher neonatal bone mineral content and lower IL-6 levels in offspring of overweight/obese women following antenatal exercise: The IMPROVE randomized controlled trial (RCT)
Colombo, Sri Lanka
Nick Shaw
Birmingham, UK
Sat 22 13:50
Challenge the Expert
Case 2: 4-year old boy with terrible leg pain post bone marrow transplant: Infection? Scurvy? Other?
Birmingham, UK
Sat 22 16:15
IS2
Two years in review
Highlights in clinical bone research
Birmingham, UK
William Singleton
Bristol, UK
Sun 23
P148
Moderated ePosters
Management of foramen magnum stenosis in patients with achondroplasia: relative merit of clinical and radiological indications for foramen magnum decompression
Bristol, UK
Sivagamy Sithambaran
Sheffield, UK
Mon 24
P27
Moderated ePosters
Response to mechanical stimulation of bone in children with osteogenesis imperfecta and the effect of bisphosphonate therapy
Sheffield, UK
Cristina Sobacchi
Milan, Italy
Mon 24 09:00
IS9
Bone cells
Osteoclast disorders
Milan, Italy
Ondrej Soucek
Prague, Czech Republic
Sun 23
P209
Moderated ePosters
Persistently low trabecular bone mineral density and normal bone strength at the radius over 3 years after simultaneous pancreas kidney transplantation
Prague, Czech Republic
Tiahna Spencer
Bethesda, USA
Sun 23
P80
Moderated ePosters
Characterization of pain in patients with fibrous dysplasia
Bethesda, USA
Lewis Steell
Glasgow, UK
Mon 24
P185
Allied Health Professionals Session
High impact exercise to improve musculoskeletal outcomes in Crohn's disease: a feasibility questionnaire
Glasgow, UK
Shinji Takeyar
Osaka, Japan
Mon 24 11:30
OC13
Oral Communications
Analysis of osteogenesis imperfecta in pathology and the effects of 4-phenylbutyric acid using patient-derived fibroblasts and induced pluripotent stem cells
Osaka, Japan
Jocely Tan
Fremantle, Australia
Mon 24
P177
Allied Health Professionals Session
Feasibility of a 13-week targeted exercise intervention on tibial bone mineral density in adolescents with Developmental Coordination Disorder
Fremantle, Australia
Josephine Tauer
Montreal, Canada
Tue 25 10:50
LB1
Oral Communications
Genetic inactivation of osteocalcin in Col1a1Jrt/+ mice, a model of dominant osteogenesis imperfecta, restores glucose metabolism to wild-type levels
Montreal, Canada
Kebashni Thandrayen
Johannesburg, South Africa
Mon 24
P44
Moderated ePosters
Bone mass and vertebral fractures in South African (SA) children on prolonged oral glucocorticoids (GCs) for chronic non-malignant illnesses
Johannesburg, South Africa
Hans Thodberg
Hørsholm, Denmark
Mon 24
P11
Moderated ePosters
Reference values of cortical thickness, bone width, and Bone Health Index in metacarpals of children from age 0 y, as determined with an extension of the fully automated BoneXpert bone age method
Hørsholm, Denmark
Jon Tobias
Bristol, UK
Sun 23 09:30
IS4
Bone development
Mechanical loading and bone development - insights from epidemiological studies
Bristol, UK
Tenna Toft
XLH-Patient Association, Denmark
Sat 22 11:20
Networking - Allied Health Professionals
The patient and parental perspective – XLH
XLH-Patient Association, Denmark
Francesca Tonelli
Pavia, Italy
Mon 24 16:30
OC19
Oral Communications
Altered 3 hydroxylation complex in bone homeostasis
Pavia, Italy
Laura Tosi
Washington, USA
Sun 23 16:00
OC7
Oral Communications
Comparison of zoledronate and pamidronate in children with skeletal disorders: short term safety experience from a single institution
Washington, USA
Ian Tucker
Sat 22 10:20
Networking - Allied Health Professionals
New treatment in XLH, case studies and results from a cohorted start to treatment
Suma Uday
Sun 23
P98
Moderated ePosters
The effect of vitamin D on bone health assessed by radiogrammetry: a double-blind placebo-controlled vitamin D supplementation trial in infants
Sun 23
P62
Moderated ePosters
Tissue non-specific alkaline phosphatase activity and mineralization capacity of bi-allelic mutations from severe perinatal and asymptomatic hypophosphatasia phenotypes: Results from an in-vitro mutagenesis model
Dorthe Viuff
Hellerup, Denmark
Tue 25 10:20
OC25
Oral Communications
TransCon CNP: Potential for a once weekly novel therapy in children with achondroplasia
Hellerup, Denmark
Leanne Ward
Ontario , Canada
Sun 23 16:20
OC9
Oral Communications
Efficacy and safety of intravenous zoledronic acid for the treatment of pediatric glucocorticoid-induced osteoporosis: An international, randomized placebo-controlled trial
Ontario , Canada
Mon 24 11:40
OC14
Oral Communications
Burosumab resulted in greater improvement in clinical outcomes than continuation with conventional therapy in younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia
Ontario , Canada
Tue 25 12:00
IS18
Approaches to treating low bone mass disorders
Anti-resorptive therapy for the treatment of pediatric bone disorders: where do we go from here?
Ontario , Canada
Matthew Warman
Boston, USA
Sat 22 15:45
IS1
Two years in review
Highlights in basic bone research
Boston, USA
Hope Weiler
Ottawa, Canada
Sun 23 14:30
IS7
Vitamin D
Effect of vitamin D on body composition
Ottawa, Canada
Michael Whyte
Saint Louis, USA
Sun 23
P77
Moderated ePosters
Long-term efficacy profile of asfotase alfa in the treatment of patients with hypophosphatasia: a pooled analysis
Saint Louis, USA
Volha Zhukouskaya
Le Kremlin-Bicêtre, France
Sun 23
P51
Moderated ePosters
Higher dose of burosumab is needed for treatment of children with severe forms of X linked hypophosphatemia
Le Kremlin-Bicêtre, France
Sat 22 12:00
Sponsored Workshop
Sat 22 14:30
Bone fragility during childhood - beyond osteogenesis imperfecta
Infant case
Sheffield, UK
Sat 22 14:50
Bone fragility during childhood - beyond osteogenesis imperfecta
Child case
Toulouse, France
Sat 22 15:10
Bone fragility during childhood - beyond osteogenesis imperfecta
Adolescent case
Brisbane, Australia
Sun 23 11:30
OC1
Oral Communications
Association between age at puberty and bone accrual up to 25 years-old
Bristol, UK
Sun 23 11:40
OC2
Oral Communications
Adolescent pregnancy and bone density in premenopausal women
Pune, India
Sun 23 11:50
OC3
Oral Communications
Osteocyte lacunae characteristics in healthy children
Vienna, Austria
Sun 23 15:30
OC4
Oral Communications
Early life vitamin D depletion and mechanical loading determine methylation changes in the RXRA, Runx2 and osterix promoters in mice
Sheffield, UK
Sun 23 15:40
OC5
Oral Communications
Low birthweight is associated with poorer limb muscle mass and grip strength in middle age: findings from the UK Biobank Imaging Enhancement
Southampton, UK
Sun 23 15:50
OC6
Oral Communications
Anthropometric characteristics of pediatric patients with hypophosphatasia: data from the Global Hypophosphatasia Patient Registry
Linz, Austria
Sun 23 16:00
OC7
Oral Communications
Comparison of zoledronate and pamidronate in children with skeletal disorders: short term safety experience from a single institution
Washington, USA
Sun 23 16:10
OC8
Oral Communications
Bisphosphonate improves hip range of motion and pain but not femoral head sphericity. A multicentre, randomized clinical trial of children with Perthes disease
Brisbane, Australia
Sun 23 16:20
OC9
Oral Communications
Efficacy and safety of intravenous zoledronic acid for the treatment of pediatric glucocorticoid-induced osteoporosis: An international, randomized placebo-controlled trial
Ontario , Canada
Mon 24 11:00
OC10
Oral Communications
Next-generation antibody-guided enzyme replacement therapy for lysosomal storage diseases
Tarrytown, United States
Mon 24 11:10
OC11
Oral Communications
Targeting adeno-associated viral vectors to fractures and the skeleton
Westmead, Australia
Mon 24 11:20
OC12
Oral Communications
Combination treatment of a novel activin receptor IIB ligand trap and zoledronate improves muscle and bone proprieties in a mouse model of osteogenesis imperfecta
Montreal, Canada
Mon 24 11:30
OC13
Oral Communications
Analysis of osteogenesis imperfecta in pathology and the effects of 4-phenylbutyric acid using patient-derived fibroblasts and induced pluripotent stem cells
Osaka, Japan
Mon 24 11:40
OC14
Oral Communications
Burosumab resulted in greater improvement in clinical outcomes than continuation with conventional therapy in younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia
Ontario , Canada
Mon 24 11:50
OC15
Oral Communications
Sustained efficacy and safety of burosumab, a fully human anti-FGF23 monoclonal antibody, in children and early adolescents with X-linked hypophosphatemia
Linz, Austria
Mon 24 16:00
OC16
Oral Communications
A natural history study of generalized arterial calcification of infancy (GACI) and autosomal recessive hypophosphatemic rickets (ARHR2) due to ENPP1 or ABCC6 deficiency: Interim analysis
Münster, Germany
Mon 24 16:10
OC17
Oral Communications
Growth curves for children with X-linked hypophosphatemia
Novato, United States
Mon 24 16:20
OC18
Oral Communications
Developing a human-mouse hybrid model of osteogenesis imperfecta for investigating new therapies for children
Sheffield, UK
Mon 24 16:30
OC19
Oral Communications
Altered 3 hydroxylation complex in bone homeostasis
Pavia, Italy
Mon 24 16:40
OC20
Oral Communications
Identifying the role of NBAS in bone fragility using zebrafish and exploring therapeutic targets to reverse NBAS activity
Sheffield, UK
Mon 24 16:50
OC21
Oral Communications
New mouse model with IFITM5 S42L for atypical type VI osteogenesis imperfecta
Bethesda, USA
Mon 24 17:00
OC22
Oral Communications
Bone tissue phenotyping reveals increased matrix mineralization, elevated osteocyte lacunar density and altered vascularity in a new OI mouse model carrying a leucine substitution for the BRIL p.Serine42 residue
Vienna, Austria
Tue 25 10:00
OC23
Oral Communications
Effects of the FGF2 aptamer on growth plate cartilage development of achondroplasia patient-specific iPS cells in a xenograft model
Osaka, Japan
Tue 25 10:10
OC24
Oral Communications
TA-46, a recombinant soluble FGFR3 receptor for the treatment of achondroplasia, is safe and well-tolerated in healthy volunteers
Basel, Switzerland
Tue 25 10:20
OC25
Oral Communications
TransCon CNP: Potential for a once weekly novel therapy in children with achondroplasia
Hellerup, Denmark
Tue 25 10:30
OC26
Oral Communications
[18F] NaF PET/CT the first tool to diagnose chronic activity in FOP at all ages?
Amsterdam, Netherlands
Tue 25 10:40
OC27
Oral Communications
Palovarotene inhibits the development of new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP)
Stanmore, UK
Tue 25 10:50
LB1
Oral Communications
Genetic inactivation of osteocalcin in Col1a1Jrt/+ mice, a model of dominant osteogenesis imperfecta, restores glucose metabolism to wild-type levels
Montreal, Canada
Tue 25 10:55
LB2
Oral Communications
Lumbar spine quantitative computed tomography (QCT) is a better predictor of vertebral fracture in boys with Duchenne muscular dystrophy (DMD) than either DXA or peripheral QCT
Birmingham, UK
Sun 23 08:00
Meet the Expert
Assessment of neuromuscular function and physical activity
Manchester, UK
Sun 23 08:00
Meet the Expert
Therapeutic management of hypophosphatemic rickets
Paris, France
Sun 23 08:00
Meet the Expert
What you need to know about bone histomorphometry
Vienna, Austria
Mon 24 08:00
Meet the Expert
Bone in neuromuscular disorders
Dubai , UAE
Mon 24 08:00
Meet the Expert
Ectopic mineralization
Münster, Germany
Mon 24 08:00
Meet the Expert
Skeletal involvement in chronic kidney diseases
Chicago, USA
Tue 25 08:00
Meet the Expert
Genetic testing for recurrent fractures – when and what?
Helsinki, Finland
Tue 25 08:00
Meet the Expert
Management of fibrous dysplasia
Bethesda, USA
Tue 25 08:00
Meet the Expert
Vibration treatment
Cologne, Germany
Sat 22 13:00
LUNCH
Sat 22 15:30
COFFEE BREAK
Sat 22 19:00
Welcome Reception
Congress Centre and Gardens
Sun 23 10:30
COFFEE BREAK
Sun 23 13:00
LUNCH
Sun 23 16:30
COFFEE BREAK
Mon 24 10:30
COFFEE BREAK
Mon 24 13:00
LUNCH
Mon 24 15:30
COFFEE BREAK
Mon 24 20:00
Conference Dinner
Stieglkeller Restaurant
Tue 25 11:00
COFFEE BREAK
Sat 22
Networking - New Investigators
How did I get here?
Melbourne, Germany
Sat 22
Networking - New Investigators
Round table discussions with senior investigators: Building your profile and network, Disseminating your work, Funding your science (and yourself!), Developing your skills
Sat 22
Networking - New Investigators
Group discussion
Sat 22 10:00
Networking - Allied Health Professionals
Introduction and Housekeeping
Sat 22 10:05
Networking - Allied Health Professionals
Management of children with severe osteogenesis imperfecta / Patient experiences seen through ‘Stop Motion’ animation
Birmingham, UK
Sat 22 10:20
Networking - Allied Health Professionals
New treatment in XLH, case studies and results from a cohorted start to treatment
Sat 22 10:35
Networking - Allied Health Professionals
Imaging in metabolic bone disease
London, UK
Sat 22 10:50
Networking - Allied Health Professionals
From conception to the retailer. How to make your specialised equipment commercially available
London, UK
Sat 22 11:05
Networking - Allied Health Professionals
Surgery and rehabilitation for children with
Vienna, Austria
Sat 22 11:20
Networking - Allied Health Professionals
The patient and parental perspective – XLH
XLH-Patient Association, Denmark
Sat 22 13:30
Challenge the Expert
Case 1: Fibrous dysplasia
Bethesda, USA
Sat 22 13:50
Challenge the Expert
Case 2: 4-year old boy with terrible leg pain post bone marrow transplant: Infection? Scurvy? Other?
Birmingham, UK
Sat 22 14:10
Challenge the Expert
Case 3: Bone fragility, abnormal neurology and bleeding disorder – a challenging case
Brisbane, Australia
Sat 22 16:50